Immune therapy in sepsis; are we ready to try again?

File Description SizeFormat 
JICS review article submitted - proof.pdfAccepted version758.1 kBAdobe PDFView/Open
Title: Immune therapy in sepsis; are we ready to try again?
Authors: Davies, R
O’Dea, K
Gordon, A
Item Type: Journal Article
Abstract: Immune-therapy to ease the burden of sepsis has thus far failed to consistently improve patient outcomes. Advances in cancer immune-therapy and awareness that prolonged immune suppression in sepsis can leave patients vulnerable to secondary infection and death, have driven resurgence in the field of sepsis immune-therapy investigation. As we develop and evaluate these novel therapies, we must learn from past experiences where single-mediator targeted immune-therapies were blindly delivered to heterogeneous patient cohorts with complex and evolving immune responses. Advances in genomics, proteomics, metabolomics, and point-of-care technology, coupled with a better understanding of sepsis pathogenesis have meant that personalised immune-therapy is on the horizon. Here we review the complex immune pathogenesis in sepsis and the contemporary immune therapies that are being investigated to manipulate this response. An outline of the immune biomarkers that may be used to support this approach is also provided.
Issue Date: 1-Nov-2018
Date of Acceptance: 9-Feb-2018
ISSN: 1751-1437
Publisher: SAGE Publications
Start Page: 326
End Page: 344
Journal / Book Title: Journal of the Intensive Care Society
Volume: 19
Issue: 4
Copyright Statement: © The Intensive Care Society 2018. Article reuse guidelines: The final, definitive version of this paper has been published in Journal of the Intensive Care Society by Sage Publications Ltd. All rights reserved. It is available at:
Sponsor/Funder: Intensive Care Society
Funder's Grant Number: Care Fndn New Investigator Awd
Publication Status: Published
Online Publication Date: 2018-04-04
Appears in Collections:Division of Surgery
Faculty of Medicine

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons